Metrochem API Private Limited Metrochem API Private Limited

X
[{"orgOrder":0,"company":"OWP Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OWP Pharmaceuticals Announces Patent Application for the First-Ever Powder for Oral Liquid Formulation of Duloxetine Hydrochloride for Major Depressive and Generalized Anxiety Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"July 2020","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SPRAVATO\u00ae\u25bc (esketamine nasal spray) Data from the Phase 3b ESCAPE-TRD Study Demonstrate Superior Efficacy Compared to Quetiapine Extended-Release in Treatment-Resistant Major Depressive Disorder1","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"November 2022","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"(n)SPRAVATO\u00ae (esketamine)* Nasal Spray is Available for Canadian Patients","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"July 2020","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved"}]

Find Clinical Drug Pipeline Developments & Deals for Duloxetine

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            Spravato® (esketamine) is the S-enantiomer of racemic ketamine and is a non-selective, non-competitive antagonist of the N-methyl-D-aspartate (NMDA) receptor, an ionotropic glutamate receptor. It is being developed for treating resistant major depressive disorder.

            Lead Product(s): Esketamine Hydrochloride,Duloxetine

            Therapeutic Area: Psychiatry/Psychology Product Name: Spravato

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 23, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Spravato® (esketamine) is the S-enantiomer of racemic ketamine and is a non-selective, non-competitive antagonist of the N-methyl-D-aspartate (NMDA) receptor, an ionotropic glutamate receptor. It is being developed for treating resistant major depressive disorder.

            Lead Product(s): Esketamine Hydrochloride,Duloxetine

            Therapeutic Area: Psychiatry/Psychology Product Name: Spravato

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable July 22, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Duloxetine hydrochloride is a serotonin and norepinephrine reuptake inhibitor (SNRI) and the delayed-release capsules, for oral use, were first approved in the U.S. in 2004.

            Lead Product(s): Duloxetine

            Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable July 08, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY